122 related articles for article (PubMed ID: 28437531)
1. Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project.
Maddox TM; Tang F; Downs JR; Masoudi FA; Virani SS; Daugherty SL; Rumsfeld JS
JAMA Intern Med; 2017 Jun; 177(6):887-889. PubMed ID: 28437531
[TBL] [Abstract][Full Text] [Related]
2. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
[TBL] [Abstract][Full Text] [Related]
3. [The IMPROVE-IT trial].
Menozzi A; Lina D; Urbinati S; Greco C
G Ital Cardiol (Rome); 2015 Dec; 16(12):667-71. PubMed ID: 26667942
[No Abstract] [Full Text] [Related]
4. Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Packard C; Stezhka T
Expert Rev Cardiovasc Ther; 2015 May; 13(5):465-6. PubMed ID: 25865021
[TBL] [Abstract][Full Text] [Related]
5. [The IMPROVE-IT trial showed no favorable effects on well-defined and clinically relevant endpoints].
Mascitelli L; Goldstein MR
G Ital Cardiol (Rome); 2015 Dec; 16(12):739. PubMed ID: 26667950
[No Abstract] [Full Text] [Related]
6. [Letter].
Poli A
G Ital Cardiol (Rome); 2015 Dec; 16(12):739-40. PubMed ID: 26667952
[No Abstract] [Full Text] [Related]
7. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
8. Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Frishman WH
Am J Med; 2015 Nov; 128(11):1160-1. PubMed ID: 26184685
[No Abstract] [Full Text] [Related]
9. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
10. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White J; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2016 Mar; 133(13):e463. PubMed ID: 27022050
[No Abstract] [Full Text] [Related]
11. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study.
Correia LC
Arq Bras Cardiol; 2016 Mar; 106(3):247-9. PubMed ID: 27027368
[No Abstract] [Full Text] [Related]
13. Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
Michos ED; Martin SS; Blumenthal RS
Circulation; 2015 Sep; 132(13):1218-20. PubMed ID: 26330413
[No Abstract] [Full Text] [Related]
14. Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Michos ED; Martin SS; Blumenthal RS
Circulation; 2016 Mar; 133(13):e462. PubMed ID: 27022049
[No Abstract] [Full Text] [Related]
15. Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Robinson JG
Circulation; 2016 Mar; 133(13):e461. PubMed ID: 27022048
[No Abstract] [Full Text] [Related]
16. [IMPROVE-IT trial. Good news for ezetimibe and for patients].
Escobar C; Divisón JA; Seguí Díaz M
Semergen; 2015; 41(5):282-3. PubMed ID: 25630369
[No Abstract] [Full Text] [Related]
17. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Weingärtner O; Sijbrands EJG; Lütjohann D
JAMA Cardiol; 2020 Feb; 5(2):234. PubMed ID: 31895451
[No Abstract] [Full Text] [Related]
18. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Li D; McCaw ZR; Wei LJ
JAMA Cardiol; 2020 Feb; 5(2):235. PubMed ID: 31895431
[No Abstract] [Full Text] [Related]
19. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Bach RG; Cannon CP; Blazing MA
JAMA Cardiol; 2020 Feb; 5(2):235-236. PubMed ID: 31895449
[No Abstract] [Full Text] [Related]
20. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
